Scientists used a CRISPR-based screen to find that inhibiting MTHFD2 reduces disease severity in inflammatory disease models.
List view / Grid view
Inflammatory bowel disease (IBD)
Nanobubbles known as extracellular vesicles (EVs) were shown to deliver protein drugs in animal models with inflammatory diseases.
Dr Chetan Karyekar, Compound Development Team Leader at The Janssen Pharmaceutical Companies of Johnson & Johnson (J&J), explains how targeting underlying immune pathways can open the door to effectively treating more inflammatory bowel disease (IBD) patients by reducing or eliminating the chronic use of corticosteroids.
A genetic defect in patients with inflammatory bowel disease (IBD) was found to affect how intestinal epithelial cells maintain a barrier.
Dr H. Michael Shepard, CEO and CSO of Enosi Life Sciences, discusses the similarities between cancer and autoimmune diseases, highlighting how this knowledge could be used to enhance treatments.
Anti-inflammatory therapies for inflammatory bowel disease could aid recovery from COVID-19 as they target an enzyme involved in both diseases.
In this article, Aparajita Dubey discusses the role of antibodies in regulating the immune system and highlights key features that need to be considered for drug development and how this can be applied to cancer therapy.
A team has developed a predictive tool called TransComp-R which could be used to reveal whether new drugs that have been effective in animals will have positive outcomes in humans.
An area where stem cell biology and medicine are combining effectively is the establishment of new cell therapies. However, current therapies are limited to a narrow set of cell types that can be isolated or created and expanded in vitro. Dr Owen Rackham discusses how utilising computational approaches will further…
Dr Nicolas Poirier reveals how immunotherapies can be designed to recalibrate the immune system for long-term maintenance of autoimmune remission.
Research into the structure of the drug-integrin complex has enabled the creation of drugs which inhibit integrin as effectively as currently used compounds, without causing excessive bleeding.
A new process for producing organoids allows researchers to explore intestinal epithelium in isolation and could allow for the development of improved targeted treatments of diseases.
Research has found that bile acids, converted by gut microbes, act as inflammatory regulators in IBD by modulating the differentiation of T cells in the gut.
Drug Target Review lists its 10 most popular news stories from 2019, summarising the drug targets that you wanted to read about.